As of August 31, 2021, WHO has listed the following COVID-19 vaccines for emergency use:
Pfizer-BioNTech COVID-19 vaccines (e.g., COMIRNATY, Tozinameran)
AstraZeneca-Oxford COVID-19 vaccines (e.g., Covishield, Vaxzevria)
Janssen (Johnson & Johnson) COVID-19 vaccine
Moderna COVID-19 vaccine
Sinopharm BIBP COVID-19 vaccine
Sinovac-CoronaVac COVID-19 vaccine
If you participated in a US-based clinical trial and are documented to have received the full series of an “active” COVID-19 vaccine candidate, and vaccine efficacy has been independently confirmed, you are considered fully vaccinated 2 weeks after completing the vaccine series. (Currently Novavax COVID-19 vaccine meets these criteria.) Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC